SCHEMBL7871593

SCHEMBL7871593

CC(C)(CCOCOCc1ccccc1)CCN1C(=O)c2ccccc2C1=O

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.45
CASP3 P42574 3/20 0.45
MAOB P27338 4/20 0.42
RAB9A P51151 5/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
TDP1 Q9NUW8 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
MAPT P10636 1/20 0.42
POLB P06746 1/20 0.40
HPGD P15428 2/20 0.40
NPSR1 Q6W5P4 1/20 0.40
NPC1 O15118 2/20 0.40
SENP8 Q96LD8 1/20 0.40
SENP7 Q9BQF6 1/20 0.40
SENP6 Q9GZR1 1/20 0.40
TSHR P16473 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27885827 0.86 TDP1 (0.49) MAPK1MAOBRAB9ASMN1; SMN2TDP1
SCHEMBL9837069 0.76 MAPK1 (0.56) MAPK1CASP3MAOBRAB9ASMN1; SMN2
SCHEMBL816698 0.76 MAPK1 (0.57) MAPK1CASP3MAOBRAB9ASMN1; SMN2
SCHEMBL7842579 0.76 TSHR (0.42) TDP1L3MBTL1POLBTSHR
SCHEMBL8909724 0.74 TSHR (0.44) TDP1L3MBTL1POLBTSHR
SCHEMBL6043712 0.74 MAPT (0.64) MAPK1CASP3MAOBRAB9ASMN1; SMN2
SCHEMBL7846503 0.74 CA1 (0.38) RAB9ASMN1; SMN2L3MBTL1MAPTHPGD
SCHEMBL7872361 0.74 HPGD (0.43) MAPK1CASP3MAOBRAB9ASMN1; SMN2
SCHEMBL15894480 0.73 HPGD (0.57) MAPK1CASP3RAB9ASMN1; SMN2TDP1
SCHEMBL7872352 0.72 GLS (0.47)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010051631-A1 Tricyclic compounds, their production and use TAKATANI MUNEO (JP) 2001-12-13 US disclosed
US-6251905-B1 Tricyclic compounds, their production and use TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-06-26 US disclosed
US-5958942-A HAVING EXCELLENT PDGF-INHIBITING ACTIVITIES, ANTIHYPERTENSIVE ACTIVITIES, ACTIVITIES OF AMELIORATING RENAL DISEASES AND ACTIVITIES OF LOWERING LIPID LEVEL. TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1999-09-28 US disclosed
EP-0771319-A1 TRICYCLIC COMPOUNDS, THEIR PRODUCTION AND USE Takeda Chemical Industries, Ltd. (JP) 1997-05-07 EP disclosed
WO-1996002542-A1 TRICYCLIC COMPOUNDS, THEIR PRODUCTION AND USE TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1996-02-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010051631-A1 Tricyclic compounds, their production and use PDGFA, HGF, REN MAPK1 418/4885CASP3 2122/4885MAOB 125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.